Onco-Innovations Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has announced the successful completion of a pilot project with Kuano Ltd. that leverages artificial intelligence and quantum-based computational analysis to advance the company’s PNKP Inhibitor Technology (ONC010). The collaboration aimed to refine the understanding of how the PNKP inhibitor and related analogs interact with their target, producing a refined structural hypothesis for PNKP inhibition and establishing a framework for structure-based optimization and future evaluation.

The pilot project applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on analysis. According to the company, the results are expected to support future initiatives including quantum-based QSAR modeling, toxicity mapping, and AI-assisted generative compound design. These approaches are intended to improve compound prioritization and accelerate progress toward preclinical development.

This development is significant because PNKP (polynucleotide kinase/phosphatase) is an enzyme involved in DNA repair pathways, and its inhibition is a promising strategy for cancer therapy. By disrupting DNA repair in cancer cells, PNKP inhibitors can enhance the effectiveness of radiation and chemotherapy. Onco-Innovations’ exclusive worldwide license to patented technology targeting solid tumors positions the company to potentially address a critical need in oncology.

The use of AI and quantum computing in drug discovery represents a cutting-edge approach that can reduce the time and cost of developing new therapies. Traditional drug development often takes over a decade and costs billions of dollars, but computational methods can streamline the identification of lead compounds and predict their behavior more efficiently. For Onco-Innovations, this pilot project marks a step toward leveraging these technologies to overcome bottlenecks in the preclinical phase.

The implications of this announcement extend beyond Onco-Innovations. As more biotech firms adopt AI and quantum computing, the entire drug discovery process could become faster and more precise. This could lead to a new wave of targeted therapies reaching patients sooner. However, the field is still emerging, and the practical application of these tools in regulatory approval processes remains to be seen.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. For more information, visit the company’s newsroom at https://ibn.fm/ONNVF.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Onco-Innovations Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program.

The post Onco-Innovations Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program appeared first on citybuzz.